<DOC>
	<DOC>NCT01713075</DOC>
	<brief_summary>The purpose of the investigation is to confirm the safety and efficacy in long-term use of Symbicort Turbuhaler in patients with Chronic obstructive pulmonary disease (COPD) under the post-marketing actual use.</brief_summary>
	<brief_title>Symbicort Turbuhaler 30/60 Special Clinical Experience Investigation for Long-term Use for Chronic Obstructive Pulmonary Disease (COPD) Patients</brief_title>
	<detailed_description>Symbicort Turbuhaler 30/60 Special Clinical Experience Investigation for long-term use for COPD patients</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases, Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
	<mesh_term>Budesonide, Formoterol Fumarate Drug Combination</mesh_term>
	<criteria>Among patients treated with Symbicort Turbuhaler due to chronic obstructive pulmonary disease(COPD), those who received the drug for the first time.</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>chronic obstructive pulmonary disease</keyword>
	<keyword>Symbicort</keyword>
	<keyword>long-term use</keyword>
</DOC>